Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

159
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
159
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

600
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
600
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

119
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
119
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Drug Therapy01:28

Drug Therapy

449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Vaccine hesitancy: discourse analysis of parents who have not fully or partially vaccinated their children].

Gaceta sanitaria·2017
Same author

[Emergency management of acute urinary retention in men].

Atencion primaria·2013
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:15

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

187

[A prudent deprescription model].

Joaquín Hortal Carmona1, Iván Aguilar Cruz1, Francisco Parrilla Ruiz1

  • 1Unidad de Urgencias y Hospitalización Polivalente, Hospital de Alta Resolución de Guadix, Guadix, Granada, España.

Medicina Clinica
|May 6, 2014
PubMed
Summary

Deprescribing involves carefully stopping medications that offer no benefit or cause harm. This process helps healthcare systems redirect resources from ineffective treatments to those that truly help patients.

Keywords:
DeprescribiendoDeprescribingDeprescripciónDeprescriptionDiscontinuationDrug withdrawalFarmacolisisPharmacolysisRetirada de medicación

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K
Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.4K

Related Experiment Videos

Last Updated: Apr 30, 2026

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
06:15

Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint

Published on: January 9, 2026

187
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K
Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.4K

Area of Science:

  • Pharmacology
  • Health Services Research
  • Geriatrics

Context:

  • Healthcare systems rely on medication prescribing.
  • Lack of incentives for reassessing and discontinuing medications with poor risk/benefit profiles.
  • Potential for resource misallocation to non-beneficial or harmful treatments.

Purpose:

  • To introduce and define deprescribing as a complementary process to prescribing.
  • To address the issue of resource deviation towards ineffective treatments.
  • To promote thoughtful medication withdrawal.

Summary:

  • Deprescribing is a deliberate process of medication withdrawal.
  • It aims to counteract the tendency for medication accumulation in patient histories.
  • This practice seeks to optimize the risk/benefit ratio of treatments and conserve healthcare resources.

Impact:

  • Potential to improve patient safety by removing harmful medications.
  • Opportunity to reduce healthcare costs by discontinuing non-beneficial treatments.
  • Enhances the efficient allocation of medical resources towards effective therapies.